Last reviewed 2026-06-10 · How we verify

Primary malignant neoplasm of brain — Treatment Landscape & Competitive Intelligence

Primary malignant neoplasm of brain (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Primary malignant neoplasm of brain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Meiji Seika Pharm · 1 drug in Primary malignant neoplasm of brain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Primary malignant neoplasm of brain:

• Primary malignant neoplasm of brain treatment updates — RSS
• Primary malignant neoplasm of brain treatment updates — Atom
• Primary malignant neoplasm of brain treatment updates — JSON

Cite this brief

Drug Landscape (2026). Primary malignant neoplasm of brain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-malignant-neoplasm-of-brain. Accessed 2026-06-10.

Related

• Primary malignant neoplasm of brain full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing